



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

SW157765

Cat. No.:	HY-139047
CAS No.:	332063-87-3
Molecular Formula:	C ₁₉ H ₁₃ N ₃ O ₃
Molecular Weight:	331.32
Target:	GLUT
Pathway:	Membrane Transporter/Ion Channel
Storage:	Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month



SOLVENT & SOLUBILITY

In Vitro

DMSO : 25 mg/mL (75.46 mM; ultrasonic and warming and heat to 60°C)

	Solvent Concentration	Mass	1 mg	5 mg	10 mg
Preparing Stock Solutions	1 mM		3.0182 mL	15.0911 mL	30.1823 mL
	5 mM		0.6036 mL	3.0182 mL	6.0365 mL
	10 mM		0.3018 mL	1.5091 mL	3.0182 mL

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description

SW157765 is a selective non-canonical glucose transporter GLUT8 (SLC2A8) inhibitor. KRAS/KEAP1 double mutant NSCLC cells are selectively sensitive to the SW157765, due to the convergent consequences of dual KRAS and NRF2 modulation of metabolic and xenobiotic gene regulatory programs^{[1][2]}.

In Vitro

SW157765-sensitive NSCLC cell lines are also selectively sensitive to glucose deprivation and to GLUT8 depletion. SW157765 selectively inhibits fluorescent 2-deoxyglucose (2DG) uptake in SW157765-sensitive cells in a dose-dependent manner^[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

- [1]. Pine SR, et al. Identifying therapeutic vulnerabilities in lung cancer: application of a chemistry-first approach. Transl Lung Cancer Res. 2018;7(Suppl 3):S265-S269.
- [2]. McMillan EA, et al. Chemistry-First Approach for Nomination of Personalized Treatment in Lung Cancer. Cell. 2018;173(4):864-878.e29.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA